Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.
- Author:
Robert A BURGER
1
Author Information
- Publication Type:Review
- Keywords: Vascular endothelial growth factor; Ovarian neoplasms; Endometrial neoplasms; Cervical neoplasms; Angiogenesis; Bevacizumab
- MeSH: Antibodies, Monoclonal, Humanized; Bevacizumab; Endometrial Neoplasms; Female; Ovarian Neoplasms; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A
- From:Journal of Gynecologic Oncology 2010;21(1):3-11
- CountryRepublic of Korea
- Language:English
- Abstract: This article reviews the history and current status of vascular endothelial growth factor targeted therapy for the most common gynecologic malignancies - epithelial ovarian, endometrial and cervical cancers. The biologic rationale for targeting vascular endothelial growth factor (VEGF) for these disease sites is well-founded, and pre-clinical studies have supported the development of anti-VEGF agents. Their classification, known mechanisms of action, unique toxicities and clinical development are herein explored, the latter including issues related to study design, disease site and disease setting.
